Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)

Thursday, January 27, 2022 from 2:00 PM ET to 3:00 PM ET • Hosted jointly by AST's Kidney Pancreas Community of Practice (KPCOP) and Transplant Pharmacy Community of Practice (TxPharm COP)

"Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)"
(Clinical Trial > Transplantation. 2021 Aug 1;105(8):1808-1817. doi: 10.1097/TP.0000000000003496.)

In this article:
Highly HLA sensitized patients have limited access to life-saving kidney transplantation because of a paucity of immunologically suitable donors. Imlifidase is a cysteine protease that cleaves IgG leading to a rapid decrease in antibody level and inhibition of IgG-mediated injury. This study investigates the efficacy and safety of imlifidase in converting a positive crossmatch test to negative, allowing highly sensitized patients to be transplanted with a living or deceased donor kidney.

Speaker:
- Bonnie Lonze, MD, PhD • New York University Langone Transplant Institute, New York, NY

Moderators:
- Edmund Huang, MD, FAST • Cedars-Sinai Medical Center, Los Angeles, CA
- Christopher Ensor, PharmD, FAST • AdventHealth Orlando, Orlando, FL

AST/AJT Journal Clubs are free, but registration is required.

Archive coming soon.

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.